Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
AKUMSNSE
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 10% | 10% | 6% | 6% |
| 15% | 16% | 39% | -25% |
| - | - | - | 75% |
| 6% | 2% | 9% | 8% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
AKUMS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,849.9 | ₹447476 Cr | 37 | 12.07 | 62.82 | ₹11479 Cr |
| 9,602 | ₹254764 Cr | 87.1 | 34.04 | 128.41 | ₹2568 Cr |
| 4,928.5 | ₹189423 Cr | 86.85 | 16.72 | 97.06 | ₹2163 Cr |
| 1,180.3 | ₹116658 Cr | 25.85 | 9.42 | 62.53 | ₹5040 Cr |
| 1,399 | ₹111484 Cr | 33.08 | 9.77 | 57.87 | ₹3879 Cr |
| 2,026.2 | ₹109943 Cr | 100.55 | 6.8 | 29.25 | ₹889 Cr |
| 2,500 | ₹101712 Cr | 49.79 | 13.75 | 71.08 | ₹1913 Cr |
| 1,200.4 | ₹101005 Cr | 31.35 | 5.32 | 63.99 | ₹4196 Cr |
| 1,716 | ₹99253 Cr | 26.73 | 17.95 | 96.84 | ₹3505 Cr |
| 2,100.7 | ₹96031 Cr | 17.37 | 30.95 | 154.35 | ₹5333 Cr |
| 817.6 | ₹12965 Cr | 44.44 | 6.53 | 28.62 | ₹255 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹31 Cr | ₹31 Cr | ₹29 Cr | ₹29 Cr | ₹14 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| ₹3283 Cr | ₹3016 Cr | ₹681 Cr | ₹689 Cr | ₹608 Cr | ₹884 Cr | ₹721 Cr | ₹855 Cr | ₹794 Cr | ₹710 Cr | ₹628 Cr | ₹493 Cr | ₹457 Cr |
| ₹3283 Cr | ₹3016 Cr | ₹681 Cr | ₹689 Cr | ₹608 Cr | ₹884 Cr | ₹721 Cr | ₹855 Cr | ₹794 Cr | ₹710 Cr | ₹628 Cr | ₹493 Cr | ₹457 Cr |
| ₹3313 Cr | ₹3047 Cr | ₹709 Cr | ₹717 Cr | ₹622 Cr | ₹885 Cr | ₹722 Cr | ₹856 Cr | ₹795 Cr | ₹711 Cr | ₹629 Cr | ₹494 Cr | ₹458 Cr |
| ₹18 Cr | ₹17 Cr | ₹11 Cr | ₹6 Cr | ₹3 Cr | ₹2 Cr | -₹2 Cr | ₹35 Cr | ₹29 Cr | ₹21 Cr | ₹12 Cr | ₹3 Cr | ₹1 Cr |
| ₹0 | ₹0 | ₹78 Cr | ₹115 Cr | ₹13 Cr | ₹0 | ₹10 Cr | ₹45 Cr | ₹17 Cr | ₹0 | ₹52 Cr | ₹78 Cr | ₹18 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹6 L | ₹0 | ₹0 |
| -₹153 Cr | -₹189 Cr | -₹111 Cr | -₹6 Cr | ₹20 Cr | ₹27 Cr | ₹33 Cr | ₹35 Cr | ₹34 Cr | ₹21 Cr | ₹39 Cr | ₹25 Cr | ₹25 Cr |
| ₹955 Cr | ₹102 Cr | ₹1464 Cr | ₹1111 Cr | ₹1095 Cr | ₹637 Cr | ₹524 Cr | ₹12 Cr | ₹11 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr |
| ₹49 Cr | ₹36 Cr | ₹31 Cr | ₹26 Cr | ₹24 Cr | ₹20 Cr | ₹19 Cr | ₹26 Cr | ₹25 Cr | ₹24 Cr | ₹26 Cr | ₹23 Cr | ₹21 Cr |
| ₹850 Cr | -₹52 Cr | ₹1462 Cr | ₹1246 Cr | ₹1153 Cr | ₹685 Cr | ₹586 Cr | ₹118 Cr | ₹85 Cr | ₹50 Cr | ₹123 Cr | ₹133 Cr | ₹70 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹602 Cr | ₹643 Cr | ₹532 Cr | ₹567 Cr | ₹590 Cr | ₹341 Cr | ₹423 Cr | ₹210 Cr | ₹244 Cr | ₹147 Cr | ₹151 Cr | ₹153 Cr | ₹122 Cr |
| ₹345 Cr | ₹180 Cr | ₹253 Cr | ₹246 Cr | ₹238 Cr | ₹84 Cr | ₹110 Cr | ₹119 Cr | ₹85 Cr | ₹79 Cr | ₹104 Cr | ₹83 Cr | ₹46 Cr |
| ₹73 Cr | ₹14 Cr | ₹368 Cr | ₹388 Cr | ₹338 Cr | ₹86 Cr | ₹130 Cr | ₹182 Cr | ₹143 Cr | ₹183 Cr | ₹136 Cr | ₹156 Cr | ₹139 Cr |
| ₹74 Cr | ₹58 Cr | ₹58 Cr | ₹65 Cr | ₹107 Cr | ₹68 Cr | ₹67 Cr | ₹14 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹20 Cr | ₹7 Cr |
| ₹1095 Cr | ₹894 Cr | ₹1211 Cr | ₹1266 Cr | ₹1272 Cr | ₹580 Cr | ₹730 Cr | ₹525 Cr | ₹480 Cr | ₹417 Cr | ₹396 Cr | ₹412 Cr | ₹315 Cr |
| ₹5276 Cr | ₹3905 Cr | ₹3393 Cr | ₹3235 Cr | ₹3050 Cr | ₹2152 Cr | ₹2037 Cr | ₹1535 Cr | ₹1389 Cr | ₹1200 Cr | ₹1161 Cr | ₹1042 Cr | ₹845 Cr |
| ₹99 Cr | ₹92 Cr | ₹89 Cr | ₹82 Cr | ₹98 Cr | ₹22 Cr | ₹20 Cr | ₹27 Cr | ₹25 Cr | ₹13 Cr | ₹20 Cr | ₹18 Cr | ₹15 Cr |
| ₹73 Cr | ₹14 Cr | ₹492 Cr | ₹537 Cr | ₹358 Cr | ₹97 Cr | ₹175 Cr | ₹269 Cr | ₹173 Cr | ₹195 Cr | ₹213 Cr | ₹255 Cr | ₹166 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹2445 Cr | ₹2252 Cr | ₹1893 Cr | ₹1715 Cr | ₹1542 Cr | ₹1325 Cr | ₹992 Cr | ₹940 Cr | ₹882 Cr | ₹784 Cr | ₹638 Cr | ₹546 Cr | ₹376 Cr |
| ₹989 Cr | ₹854 Cr | ₹702 Cr | ₹617 Cr | ₹521 Cr | ₹421 Cr | ₹348 Cr | ₹288 Cr | ₹232 Cr | ₹181 Cr | ₹137 Cr | ₹101 Cr | ₹72 Cr |
| ₹1456 Cr | ₹1397 Cr | ₹1191 Cr | ₹1097 Cr | ₹1021 Cr | ₹904 Cr | ₹644 Cr | ₹652 Cr | ₹649 Cr | ₹603 Cr | ₹501 Cr | ₹444 Cr | ₹304 Cr |
| ₹177 Cr | ₹160 Cr | ₹195 Cr | ₹103 Cr | ₹31 Cr | ₹17 Cr | ₹57 Cr | ₹0 | ₹0 | ₹0 | ₹7 Cr | ₹0 | ₹22 Cr |
| ₹14 L | ₹14 L | ₹14 L | ₹14 L | ₹39 L | ₹53 L | ₹56 L | ₹9 Cr | ₹12 Cr | ₹4 L | ₹18 Cr | ₹0 | ₹0 |
| ₹14 L | ₹14 L | ₹14 L | ₹14 L | ₹39 L | ₹53 L | ₹56 L | ₹9 Cr | ₹12 Cr | ₹4 L | ₹18 Cr | ₹0 | ₹0 |
| ₹76 Cr | ₹61 Cr | ₹56 Cr | ₹96 Cr | ₹86 Cr | ₹44 Cr | ₹36 Cr | ₹40 Cr | ₹26 Cr | ₹21 Cr | ₹51 Cr | ₹37 Cr | ₹52 Cr |
| ₹7 Cr | ₹9 Cr | ₹10 Cr | ₹14 Cr | ₹20 Cr | ₹29 Cr | ₹50 Cr | ₹99 L | ₹51 L | ₹3 Cr | ₹0 | ₹0 | ₹0 |
| ₹1716 Cr | ₹1631 Cr | ₹1452 Cr | ₹1311 Cr | ₹1159 Cr | ₹995 Cr | ₹787 Cr | ₹702 Cr | ₹688 Cr | ₹626 Cr | ₹580 Cr | ₹481 Cr | ₹378 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹19 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹756 Cr | ₹681 Cr | ₹630 Cr | ₹730 Cr | ₹722 Cr | ₹430 Cr | ₹398 Cr | ₹268 Cr | ₹295 Cr | ₹244 Cr | ₹289 Cr | ₹261 Cr | ₹192 Cr |
| ₹797 Cr | ₹770 Cr | ₹834 Cr | ₹845 Cr | ₹884 Cr | ₹531 Cr | ₹582 Cr | ₹473 Cr | ₹334 Cr | ₹295 Cr | ₹259 Cr | ₹273 Cr | ₹241 Cr |
| ₹1681 Cr | ₹576 Cr | ₹277 Cr | ₹150 Cr | ₹103 Cr | ₹68 Cr | ₹147 Cr | ₹21 Cr | ₹18 Cr | ₹7 Cr | ₹14 Cr | ₹12 Cr | ₹24 Cr |
| ₹24 Cr | ₹32 Cr | ₹30 Cr | ₹15 Cr | ₹9 Cr | ₹10 Cr | ₹13 Cr | ₹8 Cr | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr |
| ₹303 Cr | ₹215 Cr | ₹169 Cr | ₹139 Cr | ₹145 Cr | ₹99 Cr | ₹104 Cr | ₹64 Cr | ₹49 Cr | ₹24 Cr | ₹13 Cr | ₹10 Cr | ₹5 Cr |
| ₹3560 Cr | ₹2275 Cr | ₹1941 Cr | ₹1879 Cr | ₹1864 Cr | ₹1157 Cr | ₹1250 Cr | ₹833 Cr | ₹701 Cr | ₹574 Cr | ₹580 Cr | ₹561 Cr | ₹466 Cr |
| ₹2465 Cr | ₹1381 Cr | ₹730 Cr | ₹613 Cr | ₹592 Cr | ₹577 Cr | ₹520 Cr | ₹308 Cr | ₹221 Cr | ₹157 Cr | ₹184 Cr | ₹149 Cr | ₹151 Cr |
| ₹5276 Cr | ₹3905 Cr | ₹3393 Cr | ₹3235 Cr | ₹3050 Cr | ₹2152 Cr | ₹2037 Cr | ₹1535 Cr | ₹1389 Cr | ₹1200 Cr | ₹1161 Cr | ₹1042 Cr | ₹845 Cr |
| ₹216 | ₹199 | ₹50 | ₹50 | ₹87 | ₹6,801 | ₹5,554 | ₹7,286 | ₹6,763 | ₹6,053 | ₹5,356 | ₹4,204 | ₹3,901 |
| ₹216 | ₹199 | ₹50 | ₹50 | ₹43 | ₹62 | ₹50 | ₹66 | ₹61 | ₹55 | ₹49 | ₹38 | ₹35 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹382 Cr | ₹345 Cr | -₹45 Cr | ₹150 Cr | -₹193 Cr | ₹172 Cr | ₹114 Cr | ₹126 Cr | ₹150 Cr | ₹143 Cr | ₹89 Cr | ₹77 Cr | ₹126 Cr |
| ₹164 Cr | ₹172 Cr | ₹556 Cr | ₹158 Cr | ₹631 Cr | ₹144 Cr | ₹78 Cr | ₹74 Cr | ₹68 Cr | ₹67 Cr | ₹64 Cr | ₹59 Cr | ₹27 Cr |
| ₹722 Cr | ₹30 Cr | ₹50 Cr | -₹34 Cr | -₹352 Cr | -₹137 Cr | -₹115 Cr | -₹172 Cr | -₹13 Cr | -₹16 Cr | -₹11 Cr | -₹45 Cr | -₹135 Cr |
| ₹1269 Cr | ₹546 Cr | ₹561 Cr | ₹274 Cr | ₹87 Cr | ₹179 Cr | ₹77 Cr | ₹28 Cr | ₹204 Cr | ₹194 Cr | ₹141 Cr | ₹90 Cr | ₹17 Cr |
| ₹1181 Cr | ₹465 Cr | ₹498 Cr | ₹177 Cr | ₹32 Cr | ₹134 Cr | ₹28 Cr | -₹23 Cr | ₹157 Cr | ₹156 Cr | ₹89 Cr | ₹72 Cr | -₹15 Cr |
| -₹930 Cr | -₹548 Cr | -₹330 Cr | -₹305 Cr | -₹235 Cr | -₹109 Cr | -₹190 Cr | -₹49 Cr | -₹111 Cr | -₹128 Cr | -₹123 Cr | -₹150 Cr | -₹55 Cr |
| ₹34 Cr | ₹73 Cr | -₹108 Cr | ₹125 Cr | ₹236 Cr | -₹95 Cr | ₹233 Cr | ₹75 Cr | -₹35 Cr | -₹34 Cr | ₹37 Cr | ₹66 Cr | ₹89 Cr |
| ₹285 Cr | -₹10 Cr | ₹60 Cr | -₹4 Cr | ₹33 Cr | -₹70 Cr | ₹71 Cr | ₹3 Cr | ₹11 Cr | -₹7 Cr | ₹4 Cr | -₹11 Cr | ₹18 Cr |
| ₹101 Cr | ₹111 Cr | ₹52 Cr | ₹55 Cr | ₹22 Cr | ₹92 Cr | ₹21 Cr | ₹18 Cr | ₹7 Cr | ₹14 Cr | ₹10 Cr | ₹21 Cr | ₹3 Cr |
| ₹0 | ₹0 | -₹38 L | ₹0 | ₹0 | ₹51 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹386 Cr | ₹101 Cr | ₹111 Cr | ₹52 Cr | ₹55 Cr | ₹22 Cr | ₹92 Cr | ₹21 Cr | ₹18 Cr | ₹7 Cr | ₹14 Cr | ₹10 Cr | ₹21 Cr |
Fundamental Ratios
Consolidated
Standalone
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 3 out of 9 oscillators
RSI
64.54Buy
STOCH %K
79.93Neutral
MACD Level(12,26)
21.39Buy
Ultimate Oscillator
49.39Sell
Aroon Oscillator
94.00Buy
BOP
-0.27Sell
CCI
176.41Sell
Williams %R
-20.07Neutral
Momentum
37.05Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
797.14Buy
SMA 9
792.74Buy
EMA 21
776.65Buy
SMA 21
775.66Buy
EMA 50
735.85Buy
SMA 50
735.26Buy
EMA 200
611.38Buy
SMA 200
564.24Buy
WMA 20
783.76Buy
Pivot
Pivot
Classic
Resistance 5
939.23
Resistance 4
910.43
Resistance 3
881.63
Resistance 2
852.83
Resistance 1
838.07
Pivot
824.03
Support 1
809.27
Support 2
795.23
Support 3
766.43
Support 4
737.63
Support 5
708.83
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| 1.91% | 1.38% | 1.14% | 2.27% | 4.24% | 5.77% |
| 3.67% | 3.41% | 3.18% | 2.84% | 2.12% | 1.28% |
| 9.77% | 10.95% | 11.23% | 6.44% | 6.73% | 6.11% |
| 9.39% | 9.00% | 9.19% | 13.19% | 11.65% | 11.58% |
Bulk & block deals
Name
Icici Prudential Mutual Fund
Ruby Qc Investment Holdings Pte.ltd.
Icici Prudential Mutual Fund
Ruby Qc Investment Holdings Pte.ltd.
Smallcap World Fund Inc
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 22 Dec 2025 | Purchase | 311.52 Cr | ₹428 | 72.79 L | Bulk | 4.624404 | NSE |
| 22 Dec 2025 | Sell | 311.52 Cr | ₹428 | 72.79 L | Bulk | 4.624404 | NSE |
| 22 Dec 2025 | Purchase | 311.52 Cr | ₹428 | 72.79 L | Block | 4.624404 | NSE |
| 22 Dec 2025 | Sell | 311.52 Cr | ₹428 | 72.79 L | Block | 4.624404 | NSE |
| 06 Aug 2024 | Purchase | 194.98 Cr | ₹753.84 | 25.87 L | Bulk | 1.643354 | NSE |
Insider trading & SAST
Client name
Ruby Qc Investment Holdings Pte Ltd
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 Jan 2026 | Other | Disposal | 4.62 | — | 0 | — | 72.79 L | 22 Dec 2025 | Block Deal | — | SAST | 29(2) | — |
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the
Corporate Actions
Date
Type
Details
Company details
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Akums Drugs & Pharmaceuticals Share Price
817.60-5.70 (-0.69%)
+73.72% past 1 Year
News
Akums Drugs And Pharmaceuticals to host analyst and investor meet on 22 Sept
Equity
AKUMS
Akums Drugs And Pharmaceuticals to host analyst and investor meeting on September 2
Equity
AKUMS
Akums Drugs gains as Citi raises FY27–28 EPS estimates on CDMO, API outlook
Equity
AKUMS
Akums Drugs updates Baddi facility to expand oral manufacturing capacity by FY27
Equity
AKUMS
Akums Drugs updates API segment profitability target for FY27 and FY28
Equity
AKUMS
Akums Drugs shares update on Zambia order and Europe launch timeline
Equity
AKUMS
Akums Drugs sees improved domestic branded performance from Q3 FY27
Equity
AKUMS
Akums Drugs guides annual margins at 14% to 15% after strong Q1
Equity
AKUMS
Akums Drugs expects robust FY27 operating performance, CDMO growth stays strong
Equity
AKUMS
Akums Drugs outlines medium-term effective tax roadmap in recent concall update
Equity
AKUMS
Akums Drugs outlines Rs 300 crores capex plan for FY27 expansion
Equity
AKUMS
Akums Drugs sees trade generics business stable, limited impact on group performance
Equity
AKUMS
Akums Drugs guided for reduced API segment losses, targeting positive monthly EBITDA
Equity
AKUMS
Akums Drugs targets double digit growth in domestic branded formulations
Equity
AKUMS
Akums Drugs secures long term European CDMO contract with fixed pricing till 2032
Equity
AKUMS
Akums Drugs announces Zambia CDMO contract with phased FY27-FY28 supplies
Equity
AKUMS
Akums Drugs sees strong H1 FY27 CDMO volume growth with stable margins
Equity
AKUMS
Akums Drugs and Pharmaceuticals inform about update on disruption in operations
Equity
AKUMS
Akums Drugs resumes Haridwar manufacturing; four-day halt delays Rs 20 crore supply
Equity
AKUMS
Akums Drugs & Pharma - Quaterly Results
Equity
AKUMS

